Welcome to our dedicated page for CorMedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on CorMedix stock.
CorMedix Inc. (Nasdaq: CRMD), headquartered in Bridgewater, NJ, is a biopharmaceutical company dedicated to the development and commercialization of therapeutic products aimed at preventing and treating infectious and inflammatory diseases. The company's flagship product, DefenCath®, is targeted towards reducing the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter.
Recently, CorMedix announced its financial results for the fourth quarter and full year ended December 31, 2023, during a conference call held on March 12, 2024. The company showcased significant advancements in their product pipeline and continued efforts to expand the market reach of DefenCath®. This includes ongoing clinical trials and strategic partnerships aimed at enhancing patient safety and treatment efficacy.
DefenCath®, which combines taurolidine and heparin, has been pivotal in addressing the critical need for infection control in hemodialysis patients. The product has shown promising results in reducing bloodstream infections and is poised to make a substantial impact in the healthcare sector. CorMedix remains committed to research and development, with an emphasis on innovation and quality.
For more detailed information about DefenCath®, including safety information, prescribing guidelines, and potential adverse effects, professionals and patients are encouraged to review the full prescribing information available on the company's website.
CorMedix's financial health remains robust, bolstered by strategic investments and a clear focus on growth and sustainability. The company continues to engage with investors and stakeholders through transparent communication and regular updates on their progress.
For latest updates and detailed news about CorMedix Inc., investors and interested parties can visit the company's website and review recent press releases and financial reports.
CorMedix Inc. (Nasdaq: CRMD) announced plans to resubmit its New Drug Application (NDA) for DefenCath by mid-May 2023 after a productive Type A meeting with the FDA. The resubmission will leverage data from its existing contract manufacturing organization and a new heparin source. The FDA may conduct a pre-approval inspection during the review process. Additionally, CorMedix received a proposed New Technology Add-On Payment (NTAP) from CMS, potentially offering up to $17,111 per hospital stay for DefenCath, contingent on FDA approval by July 1, 2024. The anticipated new manufacturing process includes a 3 mL single-dose vial option. CEO Joe Todisco expressed optimism regarding NDA resubmission and the product's potential in hemodialysis infection prevention.
FAQ
What is the current stock price of CorMedix (CRMD)?
What is the market cap of CorMedix (CRMD)?
What does CorMedix Inc. specialize in?
What is DefenCath®?
Where is CorMedix Inc. headquartered?
How did CorMedix Inc. perform in the fourth quarter of 2023?
Who can use DefenCath®?
What are the potential side effects of DefenCath®?
How can safety concerns about DefenCath® be reported?
What recent events did CorMedix Inc. announce?
Who is the investor contact for CorMedix Inc.?
Where can I find more detailed information about DefenCath®?
